Page last updated: 2024-12-08
4'-hydroxyflurbiprofen
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4'-hydroxyflurbiprofen: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 157678 |
CHEMBL ID | 1394 |
CHEBI ID | 174398 |
SCHEMBL ID | 6450842 |
MeSH ID | M0180160 |
Synonyms (19)
Synonym |
---|
52807-12-2 |
CHEBI:174398 |
2-[3-luoro-4-(4-hydroxyphenyl)phenyl]propanoic acid |
FPH , |
4'-hydroxyflurbiprofen |
CHEMBL1394 |
2-(4'-hydroxy-2-fluoro-4-biphenylyl)propionic acid |
FT-0669641 |
2-[3-fluoro-4-(4-hydroxyphenyl)phenyl]propanoic acid |
4'-hydroxy flurbiprofen |
(1,1'-biphenyl)-4-acetic acid, 2-fluoro-4'-hydroxy-alpha-methyl- |
80685-20-7 |
SCHEMBL6450842 |
AKOS030255799 |
2-(2-fluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl)propanoic acid |
2-(2-fluoro-4'-hydroxy[1,1'-biphenyl]-4-yl)propanoic acid |
DTXSID40967269 |
2-fluoro-4'-hydroxy-alpha-methyl-[1,1'-biphenyl]-4-acetic acid |
2-{2-fluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl}propanoic acid |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Flurbiprofen half-life and Tmax were not different." | ( Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. Cefali, EA; Cox, S; Poynor, WJ; Sica, D, 1991) | 0.28 |
" Plasma and urine samples were collected over 24 h, and flurbiprofen and 4'-hydroxyflurbiprofen pharmacokinetic data were compared across genotypes." | ( Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Blaisdell, JA; Frye, RF; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA, 2003) | 0.55 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system." | ( Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. Bigogno, C; Biscaioli, M; Bolzoni, PT; Caruso, P; Catinella, S; Cenacchi, V; Del Giudice, E; Dondio, G; Facchinetti, F; Fontanella, L; Imbimbo, BP; Marchetti, S; Misiano, P; Moretto, N; Parini, C; Peretto, I; Puccini, P; Radaelli, S; Raveglia, LF; Riccardi, B; Rizzi, A; Rondelli, I; Villetti, G; Zandi, M, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID256360 | Percent inhibition against beta-amyloid-42 (Abeta42) secretion was evaluated in human neuroglioma cells (H4-APP695NL) at 100 uM | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. |
AID254925 | Concentration required to inhibit amyloid beta 42 peptide; nd is not determined | 2005 | Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18 | Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (23.08) | 18.2507 |
2000's | 5 (38.46) | 29.6817 |
2010's | 5 (38.46) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.57) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (30.77%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (69.23%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |